Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T21:53:13.145Z.
Calculation as of: 2026-10-06T21:53:13.145Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$828.48M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
PS Ratio
29.03
TTM Avg
20.29
3Y Avg
47.07
5Y Avg
47.07
Market Cap
$838.62M
PS Ratio
5.27
TTM Avg
3.19
3Y Avg
4.02
5Y Avg
10.18
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $828.48M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | 29.03 | 20.29 | 47.07 | 47.07 |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | 7.04 | 8.02 | 9.17 | 9.17 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 5.27 | 3.19 | 4.02 | 10.18 |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | 1.81 | 3.32 | 5.97 | 11.95 |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | N/A | N/A | N/A | N/A |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 2.15 | 2.45 | 3.11 | 6.00 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 3.08 | 2.48 | 2.06 | 2.27 |
| Alumis Inc. (ALMS)vs › | $855.38M | 115.62 | 174.59 | 129.38 | 129.38 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
